Genprex Secures Australian Patent for Reqorsa-Genentech Combo Therapy
Event summary
- IP Australia issued a Notice of Acceptance for Genprex's patent application covering Reqorsa® gene therapy combined with PD-L1 antibodies for cancer treatment.
- The patent, if granted, will strengthen Genprex's intellectual property portfolio and secure exclusivity in Australia.
- Genprex added the University of Kentucky as an additional clinical trial site for the Acclaim-3 trial.
- The Acclaim-3 trial is evaluating Reqorsa® in combination with Genentech's Tecentriq® for extensive stage small cell lung cancer (ES-SCLC).
- Interim analysis for the Phase 2 expansion portion of the Acclaim-3 trial is expected in the second half of 2026.
The big picture
Genprex's patent approval in Australia is a strategic win, reinforcing its intellectual property fortress around the Reqorsa®-Tecentriq® combination. This move aligns with broader trends in biotech, where securing global patents is crucial for market exclusivity and competitive advantage. The addition of new clinical trial sites underscores Genprex's commitment to accelerating development timelines, a key factor in the high-stakes race to bring innovative cancer therapies to market.
What we're watching
- Patent Strategy
- Whether Genprex can successfully secure additional patents in key international markets, including Europe, Canada, Brazil, China, and Israel.
- Clinical Trial Progress
- The pace at which Genprex can enroll patients and conduct interim analysis in the Acclaim-3 trial, which is critical for advancing the therapeutic combination.
- Market Exclusivity
- How the granted patent will impact Genprex's competitive positioning and ability to commercialize the Reqorsa®-Tecentriq® combination in Australia.
Related topics